相关实验视频

Updated: Jul 17, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

奇托寡糖化物通过PI3K/AKT/mTOR途径抑制CEMIP来抑制骨髓瘤恶性病变

IlJin Sim^1,2,3, WonGyom Choe³, JinJu Ri⁴

¹Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Jiefang Campus, 88 Jiefang Road, Shangcheng District, Hangzhou, 310009, China.

Medical oncology (Northwood, London, England)

|September 5, 2023

概括

素寡糖化物 (COS) 抑制骨肉瘤细胞生长,并抑制细胞迁移诱导蛋白 (CEMIP) 的表达. 这种效应与PI3K/AKT/mTOR信号通路的调节有关,为骨髓瘤提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
生物化学生物化学
分子生物学分子生物学

背景情况:

骨髓瘤是儿童和青少年常见的骨癌,以早期转移为特征.
诱导细胞迁移的蛋白质 (CEMIP) 与骨髓瘤的进展和恶性有关.
从基中提取的基托寡糖 (COS) 在各种癌症中表现出抗瘤特性.

研究的目的:

为了研究COS对骨髓瘤中CEMIP表达的影响.
探索COS行使其抗瘤活性的潜在分子机制.
确定PI3K/AKT/mTOR信号通路在COS介导的骨肉瘤抑制中的作用.

主要方法:

在体外实验中使用人类骨髓瘤细胞进行了实验,以评估COS的抑制活性.
在COS治疗后测量了CEMIP表达水平.
生物信息学分析被用来预测COS调节的潜在信号通路,重点关注与CEMIP表达相关的信号通路.
为了验证这些发现,进行了体内研究.

主要成果:

在实验室中,COS证明了对人类骨髓瘤细胞增殖的显著抑制作用.
在COS治疗过程中,CEMIP表达在体外和体内均显著抑制.
生物信息学分析和实验结果表明,COS抑制PI3K/AKT/mTOR信号通路.
由COS观察到的CEMIP表达的抑制与PI3K/AKT/mTOR通路的调制密切相关.

结论:

通过抑制细胞增殖和抑制CEMIP表达,COS表现出显著的抗骨髓瘤活性.
COS的抗瘤作用至少部分通过抑制PI3K/AKT/mTOR信号通路进行介导.
COS代表了骨髓瘤的有前途的治疗药物,需要进一步研究.

关键词:

在CEMIP中,CEMIP是指CEMIP.基托的寡糖化物基托.骨质肉瘤骨质肉瘤是什么在PI3K中,PI3K是指PI3K.路径路径路径路径路径

更多相关视频

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...